Biologic drug for eosinophilic esophagitis lowers childhood asthma risk

Young children treated for eosinophilic esophagitis (EoE) with dupilumab (a biologic medication) were less likely to develop asthma in the future compared with children who received a different treatment.

Leave a Reply